Table 1.
Study participants characteristics.
|
Previously infected (n = 37) |
Uninfected (n = 73 ) |
Total (n = 110) | ||
|---|---|---|---|---|
| Recent infection (<6 months) (n = 18) |
Earlier infection (>6 months) (n = 19) |
|||
| Age, y (median (IQR)) | 40.0 (32.0-52.0) | 32.0 (27.0-42.0) | 44.0 (33.0-54.0) | 42.0 (32.0-54.0) |
| Sex, Female (%) | 12 (67) | 18 (95) | 46 (63) | 76 (69) |
| Previous infection documented by: | ||||
| Both NAAT & serology positive (%) | 15 (83) | 12 (63) | 27 (25) | |
| Only seroconversion (%) | 3 (17) | 7 (37) | 10 (9) | |
|
Time between vaccine and infection, Months (median (IQR)) |
2.0 (2.0-3.0) | 9.0 (9.0-10.0) | - | 5.5 (2.0-9.0) |
NAAT: nucleic acid amplification testing. IQR: interquartile range.